Here are three things to know.
1. Through the agreement, Allergan will get exclusive access and the option to license up to five of Editas’ experimental eye treatments, according to the report.
2. Editas developed the eye treatments using the gene-editing technique CRISPR.
3. Allergan will pay $90 million upfront toward developing the drugs with Editas.
More articles on supply chain:
Do PBMs disrupt patient-physician relationships? 6 thoughts
Which news channel covers high drug costs the most?
6 things keeping supply chain leaders up at night
